AlzeCure Pharma: AlzeCure Gets Late-Breaking Abstract on NeuroRestore ACD856 Clinical Data Accepted to AD/PD 2022 Conference

STOCKHOLM, SWEDEN / ACCESSWIRE / January 18, 2022 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6)AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule

Related Keywords

Sweden ,Stockholm ,Swedish ,Alzecure Pharma ,Johan Sandin ,Neurotrophin Trk ,Matthias Rother ,Boel Nilsson , ,Results From ,Single Ascending Dose Study ,Healthy Volunteers ,Positive Modulator ,Neurotrophin Trk Receptors ,Medical Program Director ,Nasdaq First North Premier Growth Market ,Nerve Growth Factor ,Brain Derived Neurotrophic Factor ,Alzecure ,Dharma ,Jets ,Gate ,Breaking ,Abstract ,Neurorestore ,Cd856 ,Linical ,Data ,Accepted ,022 ,Conference ,